T lymphocyte modification with the UTA microporous polyurethane vascular prosthesis: In vivo studies in rats

Sequential quantification of blood T cell subsets by immunocytofluorometry was used to investigate the immune response of microporous polyurethane vascular prostheses after intraperitoneal implantation in rats. The experimental prosthesis, as developed by the University of Texas-Arlington group (UTA), and the Mitrathane® prosthesis, as developed by Matrix Med., were implanted for 1, 2 and 6 weeks and compared with ePTFE and wounded rats without prostheses (control group). The implants were examined for histopathology by light microscopy. The percentages of CD4-(helper) and CD8-(suppressor) bearing cells of the PTFE group were significantly lower (p < 0.05) than the control group 1 week post-implantation. The UTA and the Mitrathane® grafts exhibited a significant decrease in both T cell subsets at 1 week, and CD4-bearing cells at 2 weeks. At 6 weeks, T cell subsets were similar among all groups. The ratio of CD4/CD8- cells was similar among all groups except for the PTFE group, which was lower than the control group after 1 week. Histological examination of Mitrathane® and UTA grafts showed an acute phase of inflammation which lasted at least 2 weeks. Some foreign body giant cells (FBGC) were present 2 weeks post-implantation, and encapsulation was greater than that observed with PTFE grafts. On the other hand, PTFE grafts exhibited a different pattern of inflammation compared to polyurethane grafts. PTFE implants exhibited a moderate chronic inflammatory response for the first week, as shown by the formation of FBGC. At 2 and 6 weeks, the grafts were encapsulated by a thin layer of collagenous tissue and FBGC were still present around the implants, mostly located in contact with the reinforcing mesh. Polyurethane vascular grafts apparently modified peripheral T lymphocyte populations and induced an acute phase of inflammation which lasted longer than the PTFE graft.